



CEE A

Târgu Mures

9-11 December 2015




# Management of severe peripartum bleeding

Gábor Fritúz, Balázs Hauser

*Dept. of Anesthesiology and Intensive Therapy*

*Semmelweis University*



# Hemostasis of the pregnant


- Cause/aim
  - 9 month preparation for delivery and blood loss
  - Support of the uterus (and foetus)
- Haematology
  - Blood volume, „physiologic anaemia”
  - hypercoagulation state
    - It can mask former clotting disorder
- Circulation
  - Vasodilatation
  - CO
  - blood flow of uterus  $\uparrow$  (25% of CO)
  - caval vein syndrome

## Pro-coagulation

Coagulation factors, indicators of thrombin generation and clot lysis inhibitors


## Anti-coagulation

Coagulation inhibitors, mediators and indicators of clot breakdown



# Normal values

- aPTT, INR: norm
- fibrinogen 3,5-6,5 g/L
- platelet: slightly decreased
- d-dimer: elevated
- placenta: procoagulant
  - high blood flow, harmful (much TF)



*British Journal of Anaesthesia* 112 (5): 852–9 (2014)

Advance Access publication 31 January 2014 · doi:10.1093/bja/aet480

BJA

## Peri-partum reference ranges for ROTEM® thromboelastometry



N. M. de Lange<sup>1\*</sup>, L. E. van Rheenen-Flach<sup>2</sup>, M. D. Lancé<sup>3</sup>, L. Mooyman<sup>4</sup>, M. Woiski<sup>5</sup>, E. C. van Pampus<sup>6</sup>,  
M. Porath<sup>7</sup>, A. C. Bolte<sup>2</sup>, L. Smits<sup>8</sup>, Y. M. Henskens<sup>9</sup> and H. C. Scheepers<sup>4</sup>

# ROTEM pregnant vs. non-pregnant



EXTEM

FIBTEM

CONTROL  
(non pregnant)



T3  
(pregnant)



# PPH – role of fibrinogen




Fig. 2. Individual fibrinogen plasma concentrations at H0 in women with severe (●) or non-severe (○) postpartum hemorrhage. Mean  $\pm$  SD values are reported for both groups.




Fig. 3. ROC curve of fibrinogen plasma concentration at H0 for the diagnosis of severe postpartum hemorrhage.

- No pool, decreases quickly in case of bleeding, dilution in case of volume therapy, colloids cause pseudo-elevation
- Substitution: not much in FFP ☹️

**MASSIVE BLEEDING =**

**= MASSIVE HAEMOSTATIC DISORDER**



EJA

Intensiv

*Eur J Anaesthesiol* 2013; **30**:270–382

## GUIDELINES

# Management of severe perioperative bleeding

## *Guidelines from the European Society of Anaesthesiology*

Sibylle A. Kozek-Langenecker, Arash Afshari, Pierre Albaladejo, Cesar Aldecoa Alvarez Santullano, Edoardo De Robertis, Daniela C. Filipescu, Dietmar Fries, Klaus Görlinger, Thorsten Haas, Georgina Imberger, Matthias Jacob, Marcus Lancé, Juan Llau, Sue Mallett, Jens Meier, Niels Rahe-Meyer, Charles Marc Samama, Andrew Smith, Cristina Solomon, Philippe Van der Linden, Anne Juul Wikkelsø, Patrick Wouters and Piet Wyffels

# ESA 2013


- **Traditional tests**

- **Originally designed for deficiencies and drug monitoring, NOT for prognosting bleeding or guiding clotting therapy**
- **Too slow in emergency cases**
  - **aPTT, PTT (INR)**
    - » Just until the formation of the first fibrin filaments
  - **Fibrinogen level**
    - » Indirect method: interferency with heparin, FDP, colloids
  - **Platelet count**
  - **FII, FV, FVII, FVIII, FIX, FX, FXIII**
    - » Deficiencies
  - other: e.g. D-dimer


- **Viscoelastic POC tests**

- Fast intraoperative diagnosis

# Clotting, diagnosis and therapy




$\text{INR} \uparrow, \text{apTT} \uparrow \Rightarrow$   
(fibrinogen?, AT-III?, d-dimer?)



# Side effects of infusions on clotting

- Dilution effects (cristalloids + colloids)
  - Clotting factors, plt, hgb
- Colloids
  - Inhibition of PLT function
  - Inhibition of fibrin polymerisation
  - Induction of acquired vW syndrome
  - Fibrinolytic tendency



# Massive bleeding, substitution w. FFP

**Table 1.** Critical Level of Hemostatic Factors and the Inversely Predicted Corresponding Blood Loss (95% Confidence Interval) as Percent of Calculated Blood Volume

Hemostatic factor	Critical level	Blood loss (%)
Platelets	$50 \times 10^3 / \text{mm}^3$	230 (169–294)
Fibrinogen	1.0 g/L	142 (117–169)
Prothrombin	20	201 (160–244)
Factor V	25	229 (167–300)
Factor VII	20	236 (198–277)

## Group 1 (12 ml/kg FFP)



## Group 2 (33 ml/kg FFP)

	Preinfusion	Postinfusion	Observed increment	Preinfusion	Postinfusion	Observed increment
PT (s)	22.8 (17–222)	19 (15–36)		24 (17–44)	16 (14–20)	
aPTT (s)	46.4 (30–223)	37 (30–158)		41 (28–198)	30** (24–45)	
FI (g/l)	2.7 (0.2–4.4)	3.4 (0.2–7.2)	0.4 (–1.5–2.9)	1.5 (0.4–4.5)	2.7 (1.7–4.1)	1.0 (–0.9–2.4)
FII (IU/dl)	36.5 (22–65)	56 (43–76)	16 (7–42)	35 (16–73)	83** (60–102)	41* (15–61)
FV (IU/dl)	36 (2–126)	58 (14–121)	10 (–4.7–37)	41 (10–99)	69 (39–119)	28* (–16–51)
FVII (IU/dl)	43 (6.6–99)	55 (17–114)	11 (4–32)	48 (16–91)	85** (54–127)	38* (–3–75)
FVIII (IU/dl)	146 (8–391)	159 (18–360)	10 (–49–46)	157 (58–535)	175 (120–313)	17 (–250–96)
FIX (IU/dl)	83 (29–165)	98 (41–167)	8 (–6–30)	73 (43–174)	114 (65–156)	28* (–35–53)
FX (IU/dl)	49 (28–133)	61 (50–94)	15 (–73–43)	53 (16–94)	88** (65–104)	37* (–5–65)
FXI (IU/dl)	38 (20–105)	48 (38–101)	9 (–4.3–32)	34 (15–58)	55** (41–80)	23* (6–37)
FXII (IU/dl)	39 (27–64)	57 (44–83)	30 (1–37)	30 (5–69)	73** (60–105)	44* (23–66)



# Plasma

- 75% - dynamic plasma (depends on htc)
  - We measure here, treat here
  - If the cascade activates here: DIC
- 25% - static plasma (+glycocalix)
  - Here happens everything



# Massive transfusion = dilution

**Table 2—Whole Blood Composition Compared With Component Therapy**

Whole Blood (500 mL)	Component Therapy (660 mL)
Hematocrit 38%-50%	1 unit PRBC = 335 mL with hematocrit 55%
Platelets 150-400 K/ $\mu$ L	1 unit platelets = 50 mL with $5.5 \times 10^{10}$ platelets
Plasma coagulation factors = 100%	1 unit plasma = 275 mL with 80% of the coagulation activity compared with whole blood

Thus, 1 unit PRBCs + 1 unit platelets + 1 unit FFP = 660 mL with hematocrit 29%, platelets 88 K/ $\mu$ L, and coagulation activity 65% compared with whole blood. PRBC = packed red blood cells.


# Postpartum haemorrhage (PPH)

- Leading cause of maternal mortality/morbidity
- Should be avoided
- The treatment is suboptimal in many cases
- Causes: 4Ts
- Excessive blood loss:
  - pvn delivery: >500 ml;
  - Caesarean section: >1000 ml /0-24.ó
- Severe PPH:
  - >1500ml loss or
  - Hgb↓ >40 g/L or
  - PRBC demand ↑ >4 U or
  - Demand for intervention
- How much was that?



# There have been **some** bleeding...


- Normal blood loss: pvn delivery <500ml; Caesarean section <1000ml
- Severe PPH: >1500ml or >4U PRBC or  $\Delta\text{Hb}>40$  or intervention/embolisation




Swabs with blood	ml
10x10cm swab	60
30x30cm small swab	140
45x45cm large swab	350
1kg saturated swab	1000
Ø 50cm pool on the floor	500
Ø 75cm pool on the floor	1000
Ø100cm pool on the floor	1500
Blood only in the bed	<1000
Blood in the bed and on the floor	>1000

# ROTEM during PPH

ROTEM® coagulation profiles of healthy parturients



ROTEM® coagulation profiles showing obstetric coagulopathy, e.g. during PPH



Abnormal

Placental

**Uterine**

**Placental**

retained  
factors

risk  
factor

**Laceration**

causes  
and

**Injury due**

placental

**Inflammation**

**P**

**THROMBIN**  
**Congenital coagulation disorders**

e.g. haemophilia, vWD

**Acquired coagulopathy**

e.g. DIC, hyperfibrinolysis,  
pharmacologic anticoagulation

**The major coagulopathy  
independently associated with PPH  
is low FIBRINOGEN levels**

**Previous**

# Causes of PPH – 4Ts

- **TONE**
  - Uterine atony
  - Inflammation due to infection
- **TISSUE**
  - Placental complications (e.g. placenta previa, abruption)
- **TRAUMA**
  - Physical injury (e.g. lacerations of cervix, perineum, vagina; injury during Caesarean section, etc.)
- **TROMBIN**
  - Congenital disorders
  - Acquired disorders (hyperfibrinolysis)
  - Low fibrinogen level

# Risk factors of PPH

- aPTT/INR remains normal for a long time during bleeding
- Result of lab tests tend to come slow (1 hour)
- Fast decrease in platelet count
- Fibrinogen level  $<2$  g/L; this is the first to decrease
- FIBTEM-MCF: decreases earlier than the fibrinogen level
- Infusio, FFP: dilutes the clotting factors ☹️
- Colloids: diminishes clotting ☹️
- Bleeding patient tends to become hypothermic
- Do not detect fibrinolysis


# Problems in PPH

- Delay in therapy due to underestimation of blood loss
- Delayed approach to blood products (PRBC, FFP, PLT)
- Lack of "local major haemorrhage protocols"
- Lack of knowledge and education
- Insufficient interdisciplinal communication
- Chaos
- Ideal algorithm
  - Obstetrician
  - Anesthetist
  - Hemostaseologist



# ESA 2013

- Management of PPH
  - Multidisciplinary team (obstetrician, anaesthetist, hemostaseologist)
  - Escalation protocol
    - uterotonics, surgical/endovascular procedures, procoagulants
  - Use cell saver during Caesarean section
- Diagnostics
  - The availability of aPTT and INR is not sufficient
  - TEG/ROTEM can prove coagulopathy and hyperfibrinolysis
  - Have to measure fibrinogen level for a pregnant who is bleeding
    - <2: high risk of severe PPH
- Therapy
  - Use transfusion protocol
  - Therapeutic trigger of fibrinogen level should be higher
  - Give tranexamic acid during Caesarean section and at PPHs
  - rFVIIa last choice (when fibrinogen and PLT is normal(ized))





After vaginal delivery or postoperatively after cesarean section  
© 2014: PPH-CONSENSUS-Group (D-A-Ch)

	Clinical symptoms	General/surgical measures	Medication
STEP 1	Maximal duration: 30 minutes after diagnosis	Call for senior obstetrician/inform anesthesiologist	
	<ul style="list-style-type: none"> <li><b>Vaginal bleeding</b> &gt; 500 ml after vaginal delivery &gt; 1000 ml after cesarean section</li> <li>beware: underestimation !use measuring system!</li> <li><b>Stable hemodynamics</b></li> </ul>	<ul style="list-style-type: none"> <li>2 intravenous accesses (at least 1 large bore)</li> <li>Cross match blood/emergency labs</li> <li>Volume (e.g. crystalloids/colloids)</li> <li>Foley catheter</li> <li>Measure blood loss</li> <li>Fast detection of bleeding cause (4 Ts)</li> <li>Uterine tone (Tone)</li> <li>Placental inspection (Tissue)</li> <li>Inspect via speculum (Trauma)</li> <li>Coagulation (Thrombin)</li> <li>Uterine compression - ultrasound</li> </ul>	<p><b>P A R A L L E L</b></p> <ul style="list-style-type: none"> <li><b>OXYTOCIN</b> 3-5 U as short infusion and 40 U in 30 min (controlled infusion)</li> <li><b>OR</b></li> <li><b>CARBETOCIN</b> (off-label use) 100 µg as short infusion</li> <li>Severely persistent hemorrhage STEP 2, moderately persistent hemorrhage consider</li> <li><b>MISOPROSTOL</b> (off-label use) 800 µg sublingual/rectal</li> </ul>
STEP 2	Duration maximal further 30 min. (= 60 min after diagnosis)	Call for anesthesiologist/alert OR-team/organize operating room consider transfer	
	<ul style="list-style-type: none"> <li><b>Persistente severe bleeding</b></li> <li><b>Stable hemodynamics</b></li> </ul>	<ul style="list-style-type: none"> <li>Prepare operating room</li> <li>Exclude uterine rupture</li> <li>Palpation/ultrasound</li> <li>Suspected placental retention</li> <li>Manual removal</li> <li>Curettage (controlled by ultrasound)</li> </ul>	<ul style="list-style-type: none"> <li><b>Order RBC, plasma, platelets</b> (Cross match, prepare blood products)</li> <li><b>Sulprostone</b> 500 µg (maximum 1500 µg/24h) as controlled infusion only</li> <li>2 g tranexamic acid i.v. before fibrinogen</li> <li>In case of persistent severe hemorrhage approx. 1500 ml blood loss</li> <li>Fibrinogen 2-4 g</li> <li>Consider RBC, plasma</li> </ul>
STEP 3	<ul style="list-style-type: none"> <li><b>Refractory severe bleeding with hemodynamic stability</b></li> <li><b>OR</b></li> <li><b>Hemodynamic shock</b></li> </ul>	Consider transfer/call for senior anesthesiologist Inform the persons with the best clinical expertise	
	<p><b>AIM</b></p> <ul style="list-style-type: none"> <li>Hemodynamic stability</li> <li>(Temporary) cessation of bleeding</li> <li>Improve coagulation and anemia</li> <li>Organize STEP 4</li> </ul>	<p><b>Uterine tamponade</b></p> <p><b>Balloon:</b></p> <ul style="list-style-type: none"> <li>Insert balloon under ultrasound control sufficient filling of balloon (continue sulprostone)</li> <li>Use slight traction</li> <li>Alternatively: Gauze packing of the uterus</li> </ul> <p><b>Cessation of bleeding:</b></p> <ul style="list-style-type: none"> <li>Intermediate/high-dependency care</li> <li>Deflate balloon after 12-24 hours (potentially after transfer to large center)</li> </ul> <p><b>Persistence or resurgence of bleeding:</b> (bleeding with balloon in situ or after deflation)</p> <ul style="list-style-type: none"> <li>Consider repeating balloon ("bridging")</li> <li>Go to STEP 4</li> </ul>	<p><b>Target values:</b></p> <ul style="list-style-type: none"> <li>Hemoglobin &gt; 80-100 g/l (5-6.2 mmol/l)</li> <li>Platelets &gt; 50 Gpt/l</li> <li>Systolic BP &gt; 80 mmHg</li> <li>pH ≥ 7.2</li> <li>Temperature &gt; 35° C</li> <li>Calcium &gt; 0.8 mmol/l</li> </ul>
STEP 4	<ul style="list-style-type: none"> <li><b>Persistent bleeding</b></li> </ul>	Call in the persons with the best clinical expertise	
		<p><b>Definite treatment/(surgical) therapy</b></p> <p><b>In-stable hemodynamics</b></p> <p>Stop the bleeding ↓ Laparotomy/vascular clamps/compression</p> <p><b>Stabilization</b> ↓ Hemodynamics/temperature/coagulation consider rFVIIa</p>	<p><b>Stable hemodynamics</b></p> <p><b>Definite surgical therapy</b></p> <ul style="list-style-type: none"> <li>Compression sutures</li> <li>Vascular ligation</li> <li>Hysterectomy</li> </ul> <p><b>Embolisation</b></p>
	<p><b>Criteria for transfer</b></p> <ul style="list-style-type: none"> <li>Lack of surgical or interventional equipment or lack of experienced personnel</li> <li>Temporary stop of bleeding through tamponade</li> <li>Hemodynamic stability for transport</li> <li>Existing SOP with the target hospital</li> </ul>	<p><b>Recombinant FVIIa (Off-label use!)</b></p> <ul style="list-style-type: none"> <li>Initial 60-90 µg/kg (bolus)</li> <li>Might be repeated after 20 min in case of persistent bleeding</li> </ul>	<p><b>Conditions:</b></p> <ul style="list-style-type: none"> <li>pH ≥ 7.2</li> <li>Fibrinogen &gt; 1.5 g/l</li> <li>Platelets &gt; 50 Gpt/l</li> <li>Hyperfibrinolysis excluded/treated</li> </ul>

# Step 1 (max 30 min)

**CALL FOR HELP!**

26

**Vaginal bleeding > 500/1000 ml AND  
stable haemodynamics**

- 2 large bore veins
- Cross match blood
- Volume
- Urinary catheter
- MEASURING blood loss
- Causes (4T)
  - Tone?
  - Tissue?
  - Trauma?
  - Trombin?
- Uterine compression (ultrasound)
- OXITOCIN
  - 3-5 IU as short infusion, majd  
40 IU/30 min
- or
- CARBETOCIN (off-label use)
  - 100 µg as short infusion
- Moderately persistent haemorrhage consider
  - MISOPROSTOL (off-label use) ( $\text{PGE}_1$ )
    - 100 µg SL/PR
- Severely persistent haemorrhage →  
Step 2

# Step 2 (max further 30 min) **CALL FOR HELP!**

## Persistent severe bleeding AND stable haemodynamics

## Logistics of blood products

- Prepare operating room
- Exclude uterine rupture
- Palpation / Ultrasound
- Suspected placental retention
- Manual removal
- Curettage (controlled by ultrasound)

- **SULPROSTON** (PGE<sub>2</sub>)  
500 µg (max. 1500 µg/24h) in infusion
- 2 g **tranexamic acid** IV before  
fibrinogen
- In case of severe blood loss  
(>1500 ml)
  - **Fibrinogen** 2g
  - Consider **RBC/FFP**

Semmelweis Egyetem

# Step 3

**CALL FOR HELP!**

28

**Refractory severe bleeding AND  
stable haemodynamics**

**Uterine tamponade**

or

**shock**

- **Aims:**

- Hemodynamic stability
- (Temporary) cessation of bleeding
- Improve coagulation and anemia
- Organize Step 4

- **Balloon** (or gauze packing)

- **Cessation of bleeding**

- I/HDU
- Deflate balloon after 12-24 h

- **Persistent or resurgence of bleeding**

- W. balloon in situ or after deflation
- Consider repeating balloon
- Step 4

- **Target values**

- Hb >80-100 g/L; PLT: > 50 G/L
- SBP > 80 Hgmm; pH: >7.2
- T: >35°C, Ca<sub>i</sub>: >0.8 mM/L

# Step 4

**CALL FOR HELP!**

## Persistent bleeding

### Unstable haemodynamics

- **Definite (surgical) treatment**
  - Laparotomy / vascular clamps / compression
- ↓
- **Stabilization**
  - Hemodynamics / temperature / coagulation (consider rFVIIa)

### Criteria for transfer

- Lack of surgical/interventional equipments of lack of experienced personnel
- Temporary stop of bleeding through tamponade
- Hemodynamic stability for transport
- Existing SOP in the target hospital

### Stable haemodynamics

- **Definite (surgical) treatment**
  - Compression sutures
  - Vascular ligation
  - Hysterectomy
- • **Embolisation**

### Conditions of rFVIIa

- pH >7.2
- Fibrinogen >1.5 g/L
- PLT: >50 G/L
- Hyperfibrinolysis excluded/treated

Dosage: 60-90µg/kg bolus,  
Can be repeated after 20 min

# Take Home Messages

- Vigilance (something may happen...)
- Avoid underestimation of blood loss
- Fast diagnosis and fast therapy
  - POC, if available (lab tests can be too slow)
  - Substitute differentially
  - Substitution of PRBC
- **Tranexamic acid!, fibrinogen!, platelets!**
  - give rFVIIa if everything is normal(ized)
- Importance of good organization
  - **Local interdisciplinary algorithms are needed!!!**



# Mulțumesc 😊

